Author: Rachelle Ramirez

Poster-Disease-modifying Therapy

Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS

Background: Alemtuzumab (ALE) and ocrelizumab (OCR) are widely recognized as among the highest efficacy multiple sclerosis (MS) disease...

Read More

Poster-Case Reports / Case Series

Positive Outcome with Alemtuzumab in Hispanic Puerto Rican Woman with Highly Active Multiple Sclerosis after Various Failed Disease Modifying Therapies

Background: Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS). It is an...

Read More

Poster-Disease-modifying Therapy

Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study

Background: In relapsing forms of Multiple Sclerosis, disability progression has been shown to be independent of relapses. A new concept in...

Read More

Poster-Disease-modifying Therapy

MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity

Background: NEDA or No evidence of disease activity (relapses, MRI lesions and disease progression) is increasingly used as a meaningful...

Read More

Poster-Complementary and Alternative Therapies

Remote Art Therapy Activities Proposal during a COVID-19 Pandemic in Multiple Sclerosis

Background: SARS-CoV-2 infection poses a potential threat to people with autoimmune disorders, including multiple sclerosis (MS).With the...

Read More

Poster-Case Reports / Case Series

Case Report: Lama-2 Related Muscular Dystrophy Mimicking Multiple Sclerosis

Background: There is increased prevalence of genetic testing within the field of neurology and provider awareness of genetic conditions...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Poster-Case Reports / Case Series

Long Arm Serial Casting Results in Decreased Spasticity and Improved Function for Woman with MS

Background: Spasticity is present among 60-80% of individuals with Multiple Sclerosis (Etoom et al, 2018). One-third of people with...

Read More

Poster-Disease-modifying Therapy

Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)

Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....

Read More

Poster-Case Reports / Case Series

Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate

Background: The use of disease modifying treatments (DMTs) in multiple sclerosis (MS) has been well studied and has shown to reduce...

Read More